DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics announced new data on the key drivers of Thyroid Eye Disease (TED) at the American Academy of Ophthalmology (AAO) 2022.
Category: News
CXL Ophthalmics Announces $32 Million Series A Investment Round Led by AXA IM Alts, Through its Global Health Private Equity Strategy
SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics today announced it has raised a $32 million Series A funding round led by AXA IM Alts plus a syndicate of individual investors.
Trefoil Therapeutics Announces Positive TTHX1114 Phase 2 Study Data Showing Corneal Regeneration and Vision Recovery Following Descemet Stripping Only (DSO) Surgery
CHICAGO–(BUSINESS WIRE)–Trefoil Therapeutics today announced positive Phase 2 results for TTHX1114 in patients with Fuchs Endothelial Corneal Dystrophy.
CXL Ophthalmics Publishes Results of EpiSmart® Cross-Linking Phase 2 Clinical Trial for Keratoconus in Cornea
SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics today published results of the EpiSmart Cross-linking Phase 2 study for Keratoconus in Cornea.
InflammX Therapeutics Submits IND Amendment to Enable Clinical Studies with Orally Dosed Xiflam™, its NLRP3 Inflammasome-targeting Program in Retinal and Kidney Disease
TAMPA, Fla.–(BUSINESS WIRE)–InflammX Therapeutics, Inc. (InflammX), a privately held biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Amendment to U.S. Food and Drug Administration (FDA), to enable the co…
Nanorattles for Rapid Detection of Multiple mRNA Cancer Biomarkers
Scientists at Duke University have developed a ‘nanorattle’ system that allows for the detection of mRNA biomarkers of cancer. The tiny structures consist of gold nanospheres with a surrounding silver nanocage, forming the so-called rattle. The nanorattles are also loaded with light scattering dyes called Raman reporters. When illuminat (Read more...)
Algae-Based Microrobots Deliver Antibiotics within Lungs
Researchers at the University of California San Diego have developed a microrobot system to treat bacterial pneumonia. The microrobots consist of living algal cells that can swim very effectively in biological fluids, allowing them to navigate throughout the lungs and deliver drugs to difficult-to-reach areas. The algal cells are studded with antib (Read more...)
Ora, Inc. Launches the Ora EyecupTM, a Revolutionary Ophthalmic Research Technology at Eyecelerator 2022
BOSTON–(BUSINESS WIRE)–Ora, Inc., the world’s leading ophthalmology clinical research firm, has formally launched a revolutionary mobile research platform, Ora EyeCupTM, which promises to transform patient data capture through high-resolution imaging…
Visus Therapeutics Expands Ophthalmic Drug Development Portfolio With Acquisition of ViewPoint Therapeutics’ Assets
SEATTLE–(BUSINESS WIRE)– #presbyopia–Visus Therapeutics Inc. expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics, Inc.
Sudo Biosciences Raises $37M Series A Financing to Advance Precision TYK2 Therapeutics
MENLO PARK, Calif.–(BUSINESS WIRE)– #SeriesA–Sudo Biosciences Raises $37M Series A Financing to Advance Precision TYK2 Therapeutics
Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction
TEL AVIV, Israel & MELBOURNE, Australia–(BUSINESS WIRE)–Azura Ophthalmics provides update on AZR-MD-001 Phase 2 clinical program targeting Meibomian Gland Dysfunction.
Global Retinal Surgery Devices Market Analysis Report 2022-2027: Major Company Profiles, Deals, Strategies, Growth Drivers and Recent Developments – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Retinal Surgery Devices Market (By Device Segment, Application, Regional Analysis), Impact of COVID-19, Company Profiles, Major Deals, Strategy and Recent Developments – Forecast to 2027” report has been added to Re…
RetinAI Expands Operations with a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies
BERN, Switzerland & BOSTON–(BUSINESS WIRE)– #AI–RetinAI Medical AG (“RetinAI”), is a leader in clinical and imaging data management software and advanced analytics for ophthalmology, is excited to announce the launch of its first U.S.-based office, …
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that i…
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
BOSTON–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the first patient has been do…
“3D print x craftsmanship” Achieved 200% in three days since eyewear brand "HYPHEN" has started crowdfunding by using KICKSTARTER
TOKYO–(BUSINESS WIRE)–New brand “HYPHEN”, researching and developing new structure of eyewear, by HYPHEN LTD. announced the spring 2023 model 2 series developed with the theme of luxury sports on the crowdfunding site KICKSTARTER. In three days from …
Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia
NASHVILLE, Tenn. & MENDRISIO, Switzerland–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, and Sintetica, S…
Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022
BOSTON–(BUSINESS WIRE)–Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that data from the ongoing P…
Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD
BEDFORD, Mass–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today an…
Microfluidic Device Mimics Embryonic Heartbeat to Stimulate Stem Cell Development
Scientists at the University of New South Wales in Australia have developed a method to produce human blood stem cell precursors from human pluripotent stem cells. The method may have use in treating cancer patients who require high doses of such blood stem cells to help replenish endogenous populations that have been destroyed by chemotherapy. [&h (Read more...)